Our team of experts brings you cancer-related news, features, and survivor stories.
Published on: June 18, 2020
The US Food and Drug Administration (FDA) has expanded the approval of the immunotherapy drug pembrolizumab (Keytruda) to include any cancer with a high tumor mutational burden (TMB-H).
Published on: April 29, 2020
The US Food and Drug Administration (FDA) approved a new type of therapy for triple-negative breast cancer that has spread to other parts of the body and hasn’t responded to other treatments.
Published on: April 22, 2020
The US Food and Drug Administration (FDA) approved the first targeted therapy for bile duct cancer. Pemazyre (pemigatinib) is for adults whose cancer has grown after at least one previous chemotherapy treatment and whose tumors have a mutation in the FGFR2 gene.
Published on: April 20, 2020
The US Food and Drug Administration (FDA) approved Jelmyto (mitomycin gel) for a type of urothelial cancer, which is a cancer of the lining of the urinary system.
If this was helpful, donate to help fund patient support services, research, and cancer content updates.